One-click Automated 3D Treatment Planning for Radiopharmaceutical Therapy

用于放射性药物治疗的一键式自动化 3D 治疗计划

• 批准号: 10550358
• 负责人: Joseph Grudzinski
• 金额: $ 20.63万
• 依托单位: VOXIMETRY, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10550358
• 关键词: 3-Dimensional; Address; Algorithms; Automation; Award; Benchmarking; Biodistribution; Cancer Patient; Characteristics; Clinical; Computer software; Deposition; Development; Discipline of Nuclear Medicine; Disseminated Malignant Neoplasm; Dose; Evaluation; Exhibits; External Beam Radiation Therapy; Funding; Goals; Grant; Hand; Healthcare Systems; Image; Intellectual Property; Label; Lead; Lymphoma; Manuals; Medical Imaging; Metastatic Prostate Cancer; Neoplasm Metastasis; Neuroendocrine Tumors; Normal tissue morphology; Organ; Outcome; Overdose; Patient-Focused Outcomes; Patients; Phase; Physicians; Physiology; Radiation; Radioactivity; Radiopharmaceuticals; Reporting; Research; Resources; Small Business Innovation Research Grant; Software Tools; Step training; Testing; Time; Treatment outcome; Tumor Tissue; Update; Work; base; cancer therapy; chemotherapy; clinical practice; cost effective; digital; dosimetry; experience; image registration; individual patient; individualized medicine; interest; neoplastic cell; personalized medicine; pharmacokinetic model; recruit; side effect; software development; tool; treatment planning; tumor; verification and validation

Radiopharmaceutical therapy (RPT) is an alternative cancer treatment to chemotherapy that has worked well in patients with lymphoma, late-stage, metastatic prostate cancer, and neuroendocrine tumors. A unique characteristic of RPT is that it is possible to calculate how much radiation energy is deposited in tumors and normal tissues within an individual patient (“dosimetry”) by imaging the radiation emitted by the RPT agent within the body. We know that patient-specific prescriptions based on absorbed dose lead to better patient outcomes. Our active Phase 2 SBIR grant aims to provide seamless integration and automation of RPT dosimetry in clinical practices that are currently ill-equipped in terms of expertise and resources to perform advanced dosimetry for RPT. To address this need we are integrating our dosimetry algorithm into an automated treatment planning solution, TorchTM, by adding additional features such as image registration, contour propagation, and pharmacokinetic modeling. However, we have identified that a lack of region of interest (ROI) segmentation is an important feature gap in the software. To address this need, Vox is requesting supplemental funding to achieve the following aims: (1) Develop free-hand and threshold-based segmentation tools to create and edit binary label volumes for normal organs and tumors in Torch. (2) Validate free-hand and threshold-based segmentation tools to create and edit binary label volumes for normal organs and tumors in Torch. Adding segmentation tools to Torch will help Vox achieve the overall goal of the Phase II SBIR award of making RPT treatment planning faster and more accurate.

放射性药物治疗（RPT）是化疗的替代癌症治疗， 在淋巴瘤、晚期、转移性前列腺癌患者中效果良好， 神经内分泌肿瘤RPT的一个独特的特点是，它可以计算有多少 放射能量沉积在个体患者体内的肿瘤和正常组织中 通过对体内的RPT试剂发出的辐射进行成像来测量放射量（“剂量测定”）。我们知道 基于吸收剂量的患者特异性处方导致更好的患者结果。我们积极 第2阶段SBIR赠款旨在提供RPT剂量测定的无缝集成和自动化， 目前在专业知识和资源方面装备不足的临床实践， RPT的先进剂量测定。为了满足这一需求，我们正在整合我们的剂量测定算法 自动化治疗计划解决方案TorchTM，通过添加其他功能， 图像配准、轮廓传播和药代动力学建模。但我们 确定缺乏感兴趣区域（ROI）分割是 软件为了满足这一需求，Vox正在申请补充资金，以实现以下目标 目标：（1）开发徒手和基于阈值的分割工具来创建和编辑二进制 Torch中正常器官和肿瘤的标记体积。(2)基于阈值的手绘 分割工具，用于在Torch中创建和编辑正常器官和肿瘤的二进制标记体积。 为Torch添加细分工具将有助于Vox实现第二阶段SBIR的总体目标 使RPT治疗计划更快，更准确。